Skip to main
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 50%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc has demonstrated robust quarterly growth in prescriptions for Auvelity, achieving an 8% increase despite a stagnant overall market, suggesting effective marketing and sales strategies. The company's strategic expansion of its sales force to 600 representatives is anticipated to enhance its sales capabilities and facilitate the execution of a significant market opportunity projected at $1.6 billion by 2035. Additionally, the potential approval of AXS-05 in Alzheimer's Disease is expected to further bolster the company's revenue prospects, positioning Axsome for accelerated commercial momentum and potential cash flow positivity by mid-2026.

Bears say

The negative outlook on Axsome Therapeutics’s stock is largely attributed to several key risks, including potential setbacks in clinical trials for major pipeline candidates, which could impede their development and market access. There are concerns regarding the company's ability to secure timely approvals for its products, as well as competition and market penetration challenges, particularly in a crowded space where innovative differentiation is lacking. Additionally, significant financial risks exist due to high research and development costs, potential for long-term dilution, and the historical difficulties the company has faced with regulatory applications.

Axsome Therapeutics (AXSM) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 50% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 16 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $214, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $214, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.